Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Burst Biologics Has Published a Peer-Reviewed Research Article on Mechanistic Study Using BioBurst Fluid for Spinal Fusion and Foot/Ankle Disorders

Burst Biologics
Posted on: 25 Oct 18
Burst Biologics Has Published a Peer-Reviewed Research Article on Mechanistic Study Using BioBurst Fluid for Spinal Fusion and Foot/Ankle Disorders

PR Newswire

BOISE, Idaho, Oct. 25, 2018

BOISE, Idaho, Oct. 25, 2018 /PRNewswire/ -- Burst Biologics announced today that it has published "Cytokines in umbilical cord blood-derived cellular product: a mechanistic insight into bone repair" in the peer-reviewed journal Regenerative Medicine. The article may be viewed online here.

Against the backdrop of the fast-growing field of regenerative medicine, this study was conducted to determine the regenerative potential of an umbilical cord blood-derived product (UCBp), and to determine the molecular mechanism by which the product could support treatment of spinal fusion and bone nonunion.

Researchers hypothesized that the proliferative, migratory, angiogenic, and osteoinductive potential of BioBurst Fluid was associated with cytokines, growth factors, and immunomodulators present in UCBp. Experiments included transwell migration, spheroid sprouting, tube formation, and osteogenic differentiation assays. This translational research study accompanies two ongoing clinical studies on BioBurst Fluid for bone consolidation in spine and foot/ankle fusions (NCT03064802 and NCT03077256).

Highlights of the Study

  • UCBp-from 33 donors was profiled in this study to identify 44 quantifiable cytokines.
  • UCBp elevated the rates of proliferation and migration of mesenchymal stem cells (MSCs) and bone marrow stromal cells.
  • UCBp-induced secretion of VEGF-A and osteoprotegerin, which promoted angiogenesis of endothelial cells and osteogenic differentiation of MSCs, respectively.

This study demonstrated that the cytokines present in UCBp stimulate cellular processes needed for bone regeneration, making BioBurst Fluid an excellent candidate for use in bone fusions and bone nonunions.

Background of the Study
In recent years, advancements in procurement, processing, and cryopreservation have allowed UCB-derived allografts to serve as adjunct interventions in regenerative therapy. Previous studies have considered the role of these stem cells in positive clinical outcomes, but underestimated the potential role of cytokines and growth factors.

With protein multiplexing, scientists at Burst Biologics profiled 44 different cytokines in the UCBp that are essential for bone repair and regeneration. Crucially, these cytokines retained biological activity, enhancing cell proliferation and cellular VEGF-A secretion in a manner that suggests a feedforward mechanism. Furthermore, administering UCBp significantly shortened overall time required for osteogenic differentiation.

Future Direction
The mechanistic insight gained from this study will be invaluable in interpreting outcomes of ongoing clinical studies. Research has revealed the key role that cytokines play in orchestrating the cellular functions of residing host cells to participate in tissue regeneration. Allografts like BioBurst Fluid offer substantial promise in orthopedic applications.

"This research study is a major step forward in demonstrating the potential of UCB-derived regenerative interventions," said Christopher D. Jones, CEO of Burst Biologics and a corresponding author of the paper. "Along with ongoing clinical studies, our research is paving the way for a better understanding of this crucial new avenue in patient care." 

About BioBurst Fluid
BioBurst Fluid is a cryopreserved umbilical cord blood (UCB) derived cellular allograft rich in growth factors, cytokines, and cells. This fluid suspension product has been used in surgical procedures to aid in bone consolidation, and is processed with a patent-pending technique designed to preserve the brand-new growth factors and cytokines found in UCB. BioBurst Fluid is a human cell/tissue-based product (HCT/P) under 21 CFR 1271 and Section 361 of the Public Health Service Act. 

About Burst Biologics
Burst Biologics is a rapidly-growing medical research and biotechnology company providing hospitals and clinicians with a range of powerful regenerative products derived from cord blood, placental tissue, and bone. With a commitment to harnessing the power of biology, the research team at Burst Biologics is conducting industry-leading research in areas like musculoskeletal, immuno-oncology, and CNS diseases. Visit the Burst Biologics research page to learn more.

 

 

View original content:http://www.prnewswire.com/news-releases/burst-biologics-has-published-a-peer-reviewed-research-article-on-mechanistic-study-using-bioburst-fluid-for-spinal-fusion-and-footankle-disorders-300736229.html

SOURCE Burst Biologics

PR Newswire
www.prnewswire.com

Last updated on: 25/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.